These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 10667462

  • 1. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 2. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL.
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [Abstract] [Full Text] [Related]

  • 3. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL.
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [Abstract] [Full Text] [Related]

  • 4. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent.
    Kennedy AR.
    Am J Clin Nutr; 1998 Dec; 68(6 Suppl):1406S-1412S. PubMed ID: 9848508
    [Abstract] [Full Text] [Related]

  • 5. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS, Serota DG, Ware JH, Crowell JA, Kennedy AR.
    Nutr Cancer; 2002 Dec; 43(2):167-73. PubMed ID: 12588697
    [Abstract] [Full Text] [Related]

  • 6. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer.
    Meyskens FL.
    Ann N Y Acad Sci; 2001 Dec; 952():116-23. PubMed ID: 11795430
    [Abstract] [Full Text] [Related]

  • 7. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor.
    Wan XS, Meyskens FL, Armstrong WB, Taylor TH, Kennedy AR.
    Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):601-8. PubMed ID: 10428197
    [Abstract] [Full Text] [Related]

  • 8. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
    Meyskens FL.
    IARC Sci Publ; 2001 Jul; 154():49-55. PubMed ID: 11220668
    [Abstract] [Full Text] [Related]

  • 9. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
    Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL.
    Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
    [Abstract] [Full Text] [Related]

  • 10. Cationized Bowman-Birk protease inhibitor as a targeted cancer chemopreventive agent.
    Ekrami H, Kennedy AR, Witschi H, Shen WC.
    J Drug Target; 1993 May; 1(1):41-9. PubMed ID: 8069543
    [Abstract] [Full Text] [Related]

  • 11. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
    Chen YW, Huang SC, Lin-Shiau SY, Lin JK.
    Carcinogenesis; 2005 Jul; 26(7):1296-306. PubMed ID: 15746161
    [Abstract] [Full Text] [Related]

  • 12. Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity.
    Malkowicz SB, Liu SP, Broderick GA, Wein AJ, Kennedy AR, Levin RM.
    Neurourol Urodyn; 2003 Jul; 22(1):54-7. PubMed ID: 12478602
    [Abstract] [Full Text] [Related]

  • 13. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.
    William WN, Papadimitrakopoulou VA.
    Cancer Prev Res (Phila); 2013 May; 6(5):375-8. PubMed ID: 23639861
    [Abstract] [Full Text] [Related]

  • 14. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay.
    Wan XS, Lu LJ, Anderson KE, Ware JH, Kennedy AR.
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):741-7. PubMed ID: 10919746
    [Abstract] [Full Text] [Related]

  • 15. Cancer prevention by protease inhibitors.
    Kennedy AR.
    Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219
    [Abstract] [Full Text] [Related]

  • 16. Studies related to the potential antigenicity of the Bowman-Birk inhibitor, an anticarcinogenic protease inhibitor isolated from soybeans.
    Maki PA, Paterson Y, Kennedy AR.
    Nutr Cancer; 1994 Sep; 22(2):185-93. PubMed ID: 14502847
    [Abstract] [Full Text] [Related]

  • 17. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
    Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR.
    Prostate; 2001 Jun 15; 48(1):16-28. PubMed ID: 11391683
    [Abstract] [Full Text] [Related]

  • 18. Distribution of the Bowman Birk protease inhibitor in mice following oral administration.
    Billings PC, St Clair WH, Maki PA, Kennedy AR.
    Cancer Lett; 1992 Mar 15; 62(3):191-7. PubMed ID: 1596863
    [Abstract] [Full Text] [Related]

  • 19. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.
    Kennedy AR, Szuhaj BF, Newberne PM, Billings PC.
    Nutr Cancer; 1993 Mar 15; 19(3):281-302. PubMed ID: 8346077
    [Abstract] [Full Text] [Related]

  • 20. Chronicles in drug discovery.
    Moral MA, Khurdayan VK, Bozzo J.
    Drug News Perspect; 2006 Oct 15; 19(8):485-9. PubMed ID: 17160149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.